SXTP

SEC source: 0001213900-24-045708 · ownership.xml · derivative · entry 2

TOOVEY STEPHEN · CIK 0001978935 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock · 4,000 shares

Expires not disclosed

F2 · security: Stephen Toovey was initially granted a total of 8,000 restricted stock units ("RSUs") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023.

F2 · shares: Stephen Toovey was initially granted a total of 8,000 restricted stock units ("RSUs") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023.

F2 · derivative.exercise_date: Stephen Toovey was initially granted a total of 8,000 restricted stock units ("RSUs") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023.

F2 · derivative.expiration_date: Stephen Toovey was initially granted a total of 8,000 restricted stock units ("RSUs") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023.

F2 · derivative.underlying_shares: Stephen Toovey was initially granted a total of 8,000 restricted stock units ("RSUs") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023.

SEC source: 0001213900-24-045706 · ownership.xml · derivative · entry 2

FIELD PAUL · CIK 0001976960 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock · 4,000 shares

Expires not disclosed

F2 · security: Paul Field was initially granted a total of 8,000 restricted stock units ("RSUs") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023.

F2 · shares: Paul Field was initially granted a total of 8,000 restricted stock units ("RSUs") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023.

F2 · derivative.exercise_date: Paul Field was initially granted a total of 8,000 restricted stock units ("RSUs") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023.

F2 · derivative.expiration_date: Paul Field was initially granted a total of 8,000 restricted stock units ("RSUs") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023.

F2 · derivative.underlying_shares: Paul Field was initially granted a total of 8,000 restricted stock units ("RSUs") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023.

SEC source: 0001213900-24-045707 · ownership.xml · derivative · entry 3

MILLER TYRONE · CIK 0001976962 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires not disclosed

F3 · security: Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock.

F3 · shares: Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock.

F3 · derivative.exercise_date: Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock.

F3 · derivative.expiration_date: Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock.

F3 · derivative.underlying_shares: Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock.

SEC source: 0001213900-24-045705 · ownership.xml · derivative · entry 3

DOW GEOFFREY S · CIK 0001977231 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires not disclosed

F3 · security: Geoffrey Dow was granted a total of 85,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock.

F3 · shares: Geoffrey Dow was granted a total of 85,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock.

F3 · derivative.exercise_date: Geoffrey Dow was granted a total of 85,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock.

F3 · derivative.expiration_date: Geoffrey Dow was granted a total of 85,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock.

F3 · derivative.underlying_shares: Geoffrey Dow was granted a total of 85,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock.

SEC source: 0001140361-24-017682 · form4.xml · nonDerivative · entry 2

Knight Therapeutics Inc · CIK 0001756235 · Former 10% Owner

KNIGHT THERAPEUTICS INTERNATIONAL SA · CIK 0001632373 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Knight Therapeutics International S.A.

Disclosed balance after: 78,803

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On July 28, 2023, 60 Degrees Pharmaceuticals, Inc. (the "Issuer"), at its sole discretion, converted 2,162 shares of Series A Non-Voting Convertible Preferred Stock (the "Preferred Stock") held by Knight Therapeutics International S.A., an Uruguayan corporation ("Knight Subsidiary") into 45,560 Common Shares, at a conversion price equal to the 10 day volume weighted average price of the Common Shares immediately prior to the conversion. The Preferred Stock has a floating conversion price. Only the Issuer can cause shares of Preferred Stock to be converted into Common Shares. The conversion price of the Preferred Stock is determined in respect of the shares of Preferred Stock that are actually converted into Common Shares by the Issuer at the time of such conversion. The timing of conversion of any shares of Preferred Stock occurrence is outside of the control of the holder of the Preferred Stock.

F2 · balance_after: After giving effect to the transaction reported on this Form 4, Knight Subsidiary directly beneficially owns 1,153,897 Common Shares, corresponding to 9.97% ownership interest based on 11,570,578 Common Shares issued and outstanding as of April 1, 2024, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer. Knight Therapeutics Inc., a Canadian corporation ("Knight Parent" and collectively with Knight Subsidiary, the "Reporting Persons") indirectly beneficially owns 1,153,897 Common Shares, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer.

F3 · balance_after: None of the Reporting Persons can cause the Preferred Stock to be converted into Common Shares, and the Reporting Persons have no control over the occurrence or timing of a conversion of the Preferred Stock by the Issuer into Common Shares. The shares of Preferred Stock are not "derivative securities." The Reporting Persons do not beneficially own any of the Common Shares underlying the Preferred Stock until such time as the Issuer actually converts shares of Preferred Stock held by the Reporting Persons into Common Shares.

F4 · ownership.direct: Knight Parent is the sole owner of Knight Subsidiary and, as a result, may be deemed the beneficial owner for purposes of Securities Exchange Act of 1934 (the "Act") of any securities of the Issuer beneficially owned by Knight Subsidiary. Knight Parent disclaims beneficial ownership over all of the Common Shares beneficially owned by Knight Subsidiary, other than for the purpose of determining obligations under the Act, and the filing of this Form 4 shall not be deemed an admission that Knight Parent is the beneficial owner of such securities for any other purpose.

SEC source: 0001140361-24-017682 · form4.xml · nonDerivative · entry 1

Knight Therapeutics Inc · CIK 0001756235 · Former 10% Owner

KNIGHT THERAPEUTICS INTERNATIONAL SA · CIK 0001632373 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Knight Therapeutics International S.A.

Disclosed balance after: 1,153,897

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On July 28, 2023, 60 Degrees Pharmaceuticals, Inc. (the "Issuer"), at its sole discretion, converted 2,162 shares of Series A Non-Voting Convertible Preferred Stock (the "Preferred Stock") held by Knight Therapeutics International S.A., an Uruguayan corporation ("Knight Subsidiary") into 45,560 Common Shares, at a conversion price equal to the 10 day volume weighted average price of the Common Shares immediately prior to the conversion. The Preferred Stock has a floating conversion price. Only the Issuer can cause shares of Preferred Stock to be converted into Common Shares. The conversion price of the Preferred Stock is determined in respect of the shares of Preferred Stock that are actually converted into Common Shares by the Issuer at the time of such conversion. The timing of conversion of any shares of Preferred Stock occurrence is outside of the control of the holder of the Preferred Stock.

F1 · price: On July 28, 2023, 60 Degrees Pharmaceuticals, Inc. (the "Issuer"), at its sole discretion, converted 2,162 shares of Series A Non-Voting Convertible Preferred Stock (the "Preferred Stock") held by Knight Therapeutics International S.A., an Uruguayan corporation ("Knight Subsidiary") into 45,560 Common Shares, at a conversion price equal to the 10 day volume weighted average price of the Common Shares immediately prior to the conversion. The Preferred Stock has a floating conversion price. Only the Issuer can cause shares of Preferred Stock to be converted into Common Shares. The conversion price of the Preferred Stock is determined in respect of the shares of Preferred Stock that are actually converted into Common Shares by the Issuer at the time of such conversion. The timing of conversion of any shares of Preferred Stock occurrence is outside of the control of the holder of the Preferred Stock.

F2 · balance_after: After giving effect to the transaction reported on this Form 4, Knight Subsidiary directly beneficially owns 1,153,897 Common Shares, corresponding to 9.97% ownership interest based on 11,570,578 Common Shares issued and outstanding as of April 1, 2024, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer. Knight Therapeutics Inc., a Canadian corporation ("Knight Parent" and collectively with Knight Subsidiary, the "Reporting Persons") indirectly beneficially owns 1,153,897 Common Shares, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer.

F3 · balance_after: None of the Reporting Persons can cause the Preferred Stock to be converted into Common Shares, and the Reporting Persons have no control over the occurrence or timing of a conversion of the Preferred Stock by the Issuer into Common Shares. The shares of Preferred Stock are not "derivative securities." The Reporting Persons do not beneficially own any of the Common Shares underlying the Preferred Stock until such time as the Issuer actually converts shares of Preferred Stock held by the Reporting Persons into Common Shares.

F4 · ownership.direct: Knight Parent is the sole owner of Knight Subsidiary and, as a result, may be deemed the beneficial owner for purposes of Securities Exchange Act of 1934 (the "Act") of any securities of the Issuer beneficially owned by Knight Subsidiary. Knight Parent disclaims beneficial ownership over all of the Common Shares beneficially owned by Knight Subsidiary, other than for the purpose of determining obligations under the Act, and the filing of this Form 4 shall not be deemed an admission that Knight Parent is the beneficial owner of such securities for any other purpose.

SEC source: 0001575872-23-001135 · ownership.xml · derivative · entry 1

MILLER TYRONE · CIK 0001976962 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Common Stock · 240,000 shares

Expires 2028-07-12

F1 · security: Non-Qualified Stock Option granted pursuant that certain Employment Agreement, dated January 1, 2023, between the Issuer and the Reporting Person, subject to terms and conditions of the Issuer's 2022 Equity Incentive Plan.

F2 · shares: Vests in 12,000 increments on the last day of each fiscal quarter (March 31st, June 30th, September 30th, December 31st).

F3 · derivative.exercise_date: Date indicated is the date of grant.

F2 · derivative.underlying_shares: Vests in 12,000 increments on the last day of each fiscal quarter (March 31st, June 30th, September 30th, December 31st).

SEC source: 0001575872-23-001134 · ownership.xml · derivative · entry 1

DOW GEOFFREY S · CIK 0001977231 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2028-07-12

F1 · security: Non-Qualified Stock Option granted pursuant that certain Employment Agreement, dated January 1, 2023, between the Issuer and the Reporting Person, subject to terms and conditions of the Issuer's 2022 Equity Incentive Plan.

F2 · shares: Vests in 15,000 increments on the last day of each fiscal quarter (March 31st, June 30th, September 30th, December 31st).

F3 · derivative.exercise_date: Date indicated is the date of grant.

F2 · derivative.underlying_shares: Vests in 15,000 increments on the last day of each fiscal quarter (March 31st, June 30th, September 30th, December 31st).